Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction

ABSTRACT: Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction

PROVIDER: PRJNA907320 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22486248_1.fastq.gz	Fastqsanger.gz
	SRR22486248_2.fastq.gz	Fastqsanger.gz
	SRR22486249_1.fastq.gz	Fastqsanger.gz
	SRR22486249_2.fastq.gz	Fastqsanger.gz
	SRR22486250_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 166

Similar Datasets

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (CUTNRUN)

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (CUTNRUN)

| PRJNA907327 | ENA

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (RNA-Seq)

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (RNA-Seq)

| PRJNA907325 | ENA

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq II)

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq II)

| PRJNA907323 | ENA

Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq I)

Project description:Cancer Cells Resistant to Immune Checkpoint Blockade Acquire Interferon-Associated Epigenetic Memory to Sustain T Cell Dysfunction (ATAC-Seq I)

| PRJNA907322 | ENA

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [RNA-Seq]

Project description:The goal of this study is to investigate if interferon signaling regulates immune checkpoint blockade in mouse melanoma model.

2016-12-01 | GSE83848 | GEO

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [ATAC-Seq]

Project description:The goal of this study is to investigate if interferon signaling regulates immune checkpoint blockade in mouse melanoma model.

2016-12-01 | GSE83847 | GEO

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

Project description:Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

| PRJNA327201 | ENA

Antibody-lectin chimeras for glyco-immune checkpoint blockade

Project description:Despite the curative potential of checkpoint blockade immunotherapy, most patients remain unresponsive to existing treatments. Glyco-immune checkpoints – interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors – have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular platform for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin “decoy receptor” domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate anticancer immune responses including phagocytosis and cytotoxicity, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumor and immune cell subsets as well as glyco-immune checkpoints, and therefore represent a new modality for cancer immunotherapy.

2025-08-13 | PXD063934 | Pride

Aurora A Kinase Inhibition Induces Accumulation of Tumor Cells in Mitosis with Restored Interferon Signaling to Potentiate Response to PD-L1 Immune Checkpoint Blockade [RNA-seq]

Project description:By arresting tumor cells in mitosis, aurora A kinase inhibition restores interferon signaling in small cell lung cancer tumor cells and cooperates with PD-L1 immune checkpoint blockade.

2023-09-26 | GSE214613 | GEO

Aurora A Kinase Inhibition Induces Accumulation of Tumor Cells in Mitosis with Restored Interferon Signaling to Potentiate Response to PD-L1 Immune Checkpoint Blockade [single cell RNA-seq]

2023-09-26 | GSE214485 | GEO